Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in Recurrent/Metastatic HNSCC
NCT04313504Phase 2Completed
- Start
- Nov 2020
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in head and neck squamous cell carcinoma (HNSCC). Started Nov 2020; status: completed.
02
Drugs
niraparibdostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04313504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313504.